Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma.
Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DT.
World J Gastroenterol. 2022 Jan 14;28(2):216-229. doi: 10.3748/wjg.v28.i2.216.
The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer.
Xu Y, Zhang P, Zhang K, Huang C.
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188634. doi: 10.1016/j.bbcan.2021.188634. Epub 2021 Oct 14.
Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment.
Kim KE, Sinn DH, Choi MS, Kim H.
PLoS One. 2022 Jan 27;17(1):e0262750. doi: 10.1371/journal.pone.0262750. eCollection 2022.
Normalization of Elevated Tumor Marker CA27-29 After Bilateral Lung Transplantation in a Patient With Breast Cancer and Idiopathic Pulmonary Fibrosis.
Copur MS, Wurdeman JM, Nelson D, Ramaekers R, Gauchan D, Crockett D.
Oncol Res. 2018 Apr 10;26(3):515-518. doi: 10.3727/096504017X15128550060375. Epub 2017 Dec 11.
Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer.
Bazargani ST, Clifford TG, Djaladat H, Schuckman AK, Wayne K, Miranda G, Cai J, Sadeghi S, Dorff T, Quinn DI, Daneshmand S.
Urol Oncol. 2019 Jan;37(1):1-11. doi: 10.1016/j.urolonc.2018.09.008. Epub 2018 Nov 20.
Tumor markers.
Seleznick MJ.
Prim Care. 1992 Dec;19(4):715-26.
Elevated serum levels of tumor marker CA19-9 in acute cholangitis.
Albert MB, Steinberg WM, Henry JP.
Dig Dis Sci. 1988 Oct;33(10):1223-5. doi: 10.1007/BF01536670.
Elevated cerebrospinal fluid beta-2 microglobulin as a tumor marker in a patient with myeloma of the central nervous system.
Alsobhi EM, Hashim IA, Abdelaal MA, Aljifri AM, Alshamy AM.
Saudi Med J. 2007 Jan;28(1):128-30.
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma.
Yousef A, Yousef M, Zeineddine MA, More A, Fanaeian M, Chowdhury S, Knafl M, Edelkamp P, Ito I, Gu Y, Pattalachinti V, Naini ZA, Zeineddine FA, Peterson J, Alfaro K, Foo WC, Jin J, Bhutiani N, Higbie V, Scally CP, Kee B, Kopetz S, Goldstein D, Strach M, Williamson A, Aziz O, Barriuso J, Uppal A, White MG, Helmink B, Fournier KF, Raghav KP, Taggart MW, Overman MJ, Shen JP.
JAMA Netw Open. 2024 Feb 5;7(2):e240260. doi: 10.1001/jamanetworkopen.2024.0260.
The significance of elevated tumor markers among patients with interstitial lung diseases.
Kwon BS, Kim ES, Lim SY, Song MJ, Kim YW, Kim HJ, Lee YJ, Park JS, Cho YJ, Yoon HI, Lee CT, Lee JH.
Sci Rep. 2022 Oct 6;12(1):16702. doi: 10.1038/s41598-022-20683-w.
